Tonix Pharmaceuticals Reports the Completion of Patient Enrollment in NDA-Enabling P-III Trial (RESILIENT) of TNX-102 SL for Fibromyalgia
Shots:
- The patient enrollment has been completed in the P-III trial evaluating TNX-102 SL (5.6mg). The results are expected in the next quarter
- The P-III trial (RELIEF) results of TNX-102 SL (5.6mg) met its pre-specified 1EPs & showed a reduction in daily pain over PBO, a higher rate of responders to TNX-102 SL (47% vs 35%), showed activity in 2EPs demonstrating improvements in sleep quality, mitigation of fatigue, and fibromyalgia-specific global symptomatic and functional recovery, was safe & well tolerated with overall AEs profile comparable to prior fibromyalgia studies
- TNX-102 SL, a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which is currently in development as a daily bedtime treatment for fibromyalgia, long COVID, alcohol use disorder & agitation in AD
Ref: Globenewswire | Image: Tonix
Related News:- Tonix Reports the First Patient Enrollment in the P-III (RESILIENT) Study of TNX-102 SL for the Management of Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
